Every Form 4 that Humana Inc. (HUM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HUM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUM filings page.
HUMANA INC (symbol: HUM) is the issuer of record for a Form 4 filing submitted to the SEC. Nundy Shantanu reported acquisition or exercise transactions in this Form 4 filing.
HUMANA INC (HUM) reported that Chief Medical Officer Shantanu Nundy received an equity grant of 2,549 shares of Humana common stock on September 1, 2026. These are structured as restricted stock units, each representing a contingent right to one share under Humana’s 2026 Stock Incentive Plan, and are exempt under Rule 16b-3(d)(1)&(3). After this award, he holds 2,549 shares directly.
Smith Paul John reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Paul John Smith received an initial grant of restricted stock units under the company’s 2026 Stock Incentive Plan and annual Director Compensation Program. The award covers 544 restricted stock units, valued at $200,000, each representing a contingent right to receive one share of Humana common stock, and will be forfeited in its entirety if his board service is less than one year.
Crawford Frederick John reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Frederick John Crawford received an initial grant of 544 restricted stock units on August 1, 2026, under the company’s 2026 Stock Incentive Plan and annual Director Compensation Program. The award, valued at $200,000, will be forfeited if his service is less than one year. He also reports 21 shares held in managed trust accounts where he has no investment control.
HILZINGER KURT J reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Kurt J. Hilzinger reported a compensation-related equity award rather than an open-market trade. On June 30, 2026, he received 233 Restricted Stock Units (RSUs) tied to Humana common stock at a reference price of $392.32 per share, classified as a grant or award.
After the reported updates, he directly holds 19,448 shares of Humana common stock and 16,534 RSUs, each representing a contingent right to receive one Humana share on a 1-for-1 basis. Footnotes explain these units arise from annual director fees, cash fee conversions, and dividend reinvestments that have been deferred until he leaves the board.
Mellet Celeste reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc.'s Chief Financial Officer, Celeste Mellet, received a grant of 15,387 shares of Humana common stock as a compensation award. The award was reported at a price of $0.00 per share, reflecting that it was a grant rather than an open-market purchase.
Following this grant, Mellet directly holds 39,637 shares of Humana common stock. This amount includes 35,172 restricted stock units, which represent a contingent right to receive one share of Humana Inc. common stock for each unit under the company's 2019 Amended & Restated and 2026 Stock Incentive Plans.
Mehta Japan reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc.’s Chief Information Officer Japan Mehta received a grant of 9,448 shares of Humana common stock, awarded at no cash cost as equity compensation. Following this award, Mehta directly holds 17,176 shares, including 15,200 restricted stock units that each represent a contingent right to one Humana share under the company’s 2019 Amended & Restated and 2026 Stock Incentive Plans, exempt under Rule 16b-3.
Humana Inc. President, Enterprise Growth, David Dintenfass reported a grant of 11,273 shares of Humana common stock at a price of $0.00 per share, raising his direct holdings to 25,407 shares.
He also holds options on 51,389 shares of Humana common stock with an exercise price of $367.21 per share, expiring on February 21, 2031, granted under Humana’s stock incentive plan and vesting in three annual increments from February 21, 2025 to February 21, 2027. His position includes 18,617 restricted stock units, each representing a contingent right to receive one share of Humana common stock.
Rechtin James A. reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. President & CEO James A. Rechtin reported an award of 35,633 shares of Humana common stock, held indirectly through two revocable trusts for the benefit of him and his spouse. After this grant, these trusts hold 63,938 shares of Humana common stock.
Rechtin also holds equity awards under Humana’s stock incentive plans, including 2,183 restricted stock units, each representing one future share of Humana common, and stock options covering 15,772 shares at $367.21 per share and 29,230 shares at $458.185 per share, generally vesting in three annual increments from 2025 to 2027 and expiring in 2031.
O'Hara Michelle A. reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. reported that Chief Human Resources Officer Michelle A. O'Hara received a grant of 10,485 shares of Humana common stock as a stock award. Following this grant, she directly holds 20,026 shares of common stock, including 17,997 restricted stock units that each represent a contingent right to receive one Humana common share under the company’s 2019 Amended & Restated and 2026 Stock Incentive Plans.
Field Robert Stuart reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Robert Stuart Field received a grant of 852 restricted stock units (RSUs) of Humana common stock. The award represents an initial grant of $200,000 in RSUs under the company’s annual Director Compensation Program and 2026 Stock Incentive Plan.
Each RSU carries a right to receive one share of Humana common stock and is reported as exempt under Rule 16b-3(d)(1) & (3). The entire award will be forfeited if his board service is less than one year. Following this grant, he directly holds 852 RSUs.
Humana Inc. Chief Legal Officer Joseph C. Ventura received 10,318 shares of Humana Common stock as a grant on May 1, 2026, at $0.00 per share, bringing his direct holdings to 27,405 shares.
He also holds 294 Humana Common shares indirectly through a retirement savings plan. In addition, he retains several option awards on Humana Common stock with exercise prices between $350.7875 and $510.2425 per share, expiring from 2027 through 2031.
Shetty Sanjay K reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. President, CenterWell Sanjay K. Shetty received a grant of 9,945 shares of Humana Common stock as compensation. The shares were awarded at a price of $0.0000 per share and increase his directly held common stock position to 22,088 shares.
The filing also shows he holds stock options giving the right to buy 6,572 Humana shares at $367.21 per share expiring on February 21, 2031, and 3,964 shares at $487.1602 per share expiring on April 1, 2030. His reported holdings include 18,763 restricted stock units that can settle into Humana common shares.
Humana Inc. executive Aaron Martin received a grant of 8,206 shares of Humana common stock as a compensation award. The award was recorded at a price of $0.0000 per share and classified as a grant or other acquisition rather than an open-market purchase.
Following this transaction, Martin directly holds 25,237 restricted stock units, each representing a contingent right to receive one share of Humana Inc. common stock. These units were granted under the company’s 2019 Amended & Restated and 2026 Stock Incentive Plans and are exempt under Rule 16b-3.
Humana Inc. President, CenterWell, Sanjay K. Shetty reported equity compensation activity. On April 1, 2026, he acquired 887 shares of Humana common stock through the exercise or settlement of performance-related equity awards. On the same date, 401 shares at $175.44 per share were withheld to cover tax liabilities on performance stock vesting, with no sale proceeds received.
After these transactions, Shetty directly owns 12,143 Humana common shares, which include 8,818 restricted stock units and additional Performance Stock Units. He also holds stock options over 3,964 underlying shares at an exercise price of $487.1602 expiring on April 1, 2030, and options over 6,572 underlying shares at $367.21 expiring on February 21, 2031.
Humana Inc. President, Insurance George Renaudin reported routine compensation-related activity, including an annual contribution of 25 Phantom Stock Units based on Humana common stock at $173.39 per unit under the Humana Retirement Equalization Plan.
Following the update, he holds 199 Phantom Stock Units indirectly, 16,075 shares of Humana common stock directly and 542 shares indirectly through a retirement savings plan. He also holds stock options on 4,162 shares at an exercise price of $510.2425 expiring in 2030 and options on 6,966 shares at $367.21 expiring in 2031, plus 9,059 restricted stock units that may convert into common shares.
HILZINGER KURT J reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Kurt J. Hilzinger received a grant of 536 Restricted Stock Units on Humana Common stock as compensation. The units were valued at $170.6605 per unit and are deferred until his service as a director ends, when they will settle 1-for-1 in common shares.
Footnotes explain that his annual director fees, certain cash fees, and related dividends are taken in stock units and dividend-equivalent units, all deferred into Humana common stock. He also holds additional deferred stock units and 19,448 Humana common shares directly.
Joseph C. Ventura, Chief Legal Officer of Humana Inc., reported activity dated 2026-02-24, including an exercise or conversion involving 1,035 shares of Humana Common and a disposition of 478 shares at $177.0750 to satisfy tax liabilities on vested performance stock units, with no value received in return.
After these actions, he directly holds 17,087 shares of Humana Common and 23,920 options, plus 289 shares held indirectly through a Humana Retirement Savings Plan. Footnotes also describe additional restricted and performance stock units awarded under Humana’s 2019 Amended & Restated Stock Incentive Plan.
Humana Inc. President, Insurance George Renaudin II reported option-related activity in Humana common stock. On 02/24/2026, he acquired 1,035 shares through an exercise of stock options and disposed of 419 shares at $177.075 per share to cover tax liabilities on performance stock vesting, receiving no cash value in return.
Humana Inc. senior vice president John‑Paul W. Felter reported several equity-related transactions in Humana common stock. On February 23, 2026, he acquired 5,669 shares through a grant or award at no stated price, increasing his direct holdings.
On February 24, 2026, he acquired a further 165 shares via exercise or conversion of a derivative security, then disposed of 84 shares at $177.075 per share to cover tax liabilities tied to performance stock units vesting on that date, with no value received in return. After these transactions he directly owned 7,484 shares, which include 6,417 restricted stock units that each represent a contingent right to one share of Humana common stock and are exempt under the company’s 2019 Amended & Restated Plan. Footnotes also state that additional performance stock units are not required to be reported until vesting on February 24, 2026.
Humana Inc. executive Sanjay K. Shetty, President of CenterWell, reported an open-market purchase of Humana common stock. On this transaction date, he bought 810 shares at a price of $185.205 per share, increasing his directly held stake to 11,657 shares.
The filing also shows option holdings under Humana’s 2019 Amended & Restated Stock Incentive Plan, with 3,964 and 6,572 options from grants vesting in annual increments through 2026 and 2027. Footnotes further note 8,818 restricted stock units that each represent the right to receive one Humana common share.
Humana Inc. executive David Dintenfass, President, Enterprise Growth, reported insider equity transactions. He exercised stock options into 3,858 shares of Humana common stock under the company’s 2019 Amended & Restated Stock Incentive Plan, tied to options granted on 02/21/2024.
He also disposed of 1,182 shares at $189.655 per share to cover tax liabilities on restricted stock units that vested on 02/21/2026, a tax-withholding transaction rather than an open-market sale. After these transactions, he directly holds 14,134 shares of Humana common stock, including 7,344 restricted stock units, and 51,389 stock options representing rights to buy additional shares.
Humana Inc. Chief Information Officer Japan Mehta reported an equity award exercise and related tax withholding. On 2/13/26, Mehta acquired 1,682 shares of Humana common stock through an exercise or conversion of a derivative security at a stated price of $0.0000 per share.
On the same date, 430 shares of Humana common stock were disposed of to cover tax liabilities for shares vesting on 2/13/26, with no value received in return, at a price of $181.4575 per share. Following these transactions, Mehta directly owned 7,728 shares of Humana common stock, which includes 5,752 restricted stock units representing a contingent right to receive one share each.
Humana Inc. Chief Financial Officer Celeste Mellet exercised 7,763 derivative securities into Humana common stock and then used 4,204 shares to satisfy tax withholding for shares vesting on 2/13/26, receiving no value in return. After these transactions, she directly holds 24,250 shares, including 19,785 restricted stock units.
Humana Inc. reported that President, Medicare Advantage Aaron Martin acquired 17,031 shares of Humana common stock on 02/12/2026 through a grant of restricted stock units at a price of $0 per share. These 17,031 restricted stock units each represent a contingent right to receive one share of Humana common stock under the company’s 2019 Amended & Restated Plan.
Humana Inc. President & CEO James A. Rechtin reported routine equity award activity on January 8, 2026. A total of 2,183 restricted stock units converted into the same number of Humana common shares at $0 per share under the company’s 2019 Amended & Restated Stock Incentive Plan.
Of these shares, 980 Humana common shares were withheld at a price of $279.1475 per share to satisfy tax obligations related to vesting, with no value received in return. Following these transactions, 28,305 Humana common shares were beneficially owned indirectly through two revocable trusts for the benefit of Rechtin and his spouse, where they serve as sole trustees.
Rechtin also holds stock options covering 29,230 Humana shares at an exercise price of $458.185 and options covering 15,772 shares at $367.21, as well as 14,054 restricted stock units, all granted under the same incentive plan with multi-year vesting schedules.
Humana Inc. director David T. Feinberg reported equity transactions in company stock and stock units. On 01/02/2026, he acquired 766 shares of Humana common stock at a reported price of $0, increasing his directly held beneficial ownership to 1,207 shares.
The filing also details changes in his deferred restricted stock units (RSUs). An existing block of 1,593 RSUs remains outstanding, each representing the right to receive one share of Humana common stock. On 12/31/2025, he elected to convert a director cash fee into 70 stock units and reinvest a dividend into 29 stock units, both deferred and valued at $258.8675 per unit, bringing their respective RSU balances to 708 and 46 units. All units are payable in Humana common stock on a 1-for-1 basis under the company’s equity plan and are reported as exempt under Rule 16b-3.
Humana Inc. director Wayne A. I. Frederick reported equity transactions in Humana common stock. The filing shows a disposition of 440 shares of Humana common stock in Table I.
In Table II, he acquired 766 restricted stock units on 01/02/2026 and 35 restricted stock units on 12/31/2025, each tied to Humana common stock. Following these transactions, he directly beneficially owned 3,174 restricted stock units from the first line and 73 from the second.
According to the footnotes, the larger grant represents an annual director’s fee payable in stock units under Humana’s 2019 Amended & Restated Plan, while the smaller amount reflects dividends reinvested into stock units. Both types of units are deferred until he resigns as a director, when they will be settled in Humana common stock on a one-for-one basis.
Humana Inc. director John W. Garratt reported equity awards and his updated holdings. On 12/31/2025, he acquired 16 restricted stock units tied to dividend payments, and on 01/02/2026 he acquired 766 restricted stock units as part of his annual director fee. These stock units are deferred until he resigns as a director, when they will be settled in Humana common stock on a 1-for-1 basis under the company’s 2019 Amended & Restated Plan.
Following these transactions, he directly beneficially owns 1,685 shares of Humana common stock. He also beneficially owns 1,929 restricted stock units described in note (1) and 18 restricted stock units described in note (2) as derivative securities, each corresponding to one share of Humana common stock upon settlement.
Humana Inc. director reports equity transactions and updated holdings. Director Marcy S. Klevorn reported activity in Humana common stock and related stock units. The filing shows a disposition of 436 shares of Humana common stock in the non-derivative section. In the derivative section, she acquired 766 restricted stock units as part of her annual director’s fee, which is payable in stock units deferred until her resignation, and 28 additional stock units from a director’s dividend payment reinvested at a price of $258.8675 per unit. Following these transactions, she beneficially owns 2,771 restricted stock units tied to Humana common stock under one award and 53 units under the dividend reinvestment award, each representing a contingent right to receive one share of Humana common stock on a 1-for-1 basis.
Humana Inc. director Frank A. D'Amelio reported new and existing equity holdings in the company. On 01/02/2026, he acquired 766 restricted stock units, which represent a contingent right to receive Humana common stock under the company’s 2019 Amended & Restated Plan. These units, along with other deferred stock units, are generally payable in Humana common stock on a 1-for-1 basis after his resignation as a director.
The filing shows a total of 26,826 restricted stock units held directly after the reported transaction, plus additional deferred stock units from converting director cash fees (2,467 units) and reinvested dividends (318 units). It also notes 20,634 Humana common shares held indirectly in a 2024 Grantor Retained Annuity Trust for which he serves as sole trustee.
Humana Inc. director Jorge S. Mesquita reported receiving 766 restricted stock units of Humana common stock on 01/02/2026. These units represent a contingent right to receive one share of Humana common stock for each unit and are noted as exempt under Rule 16b-3(d)(1)&(3) pursuant to the company's 2019 Amended & Restated Plan.
Following this grant, a total of 4,127 Humana shares, including the 766 restricted stock units, are reported as beneficially owned indirectly through a revocable trust where Mesquita is the sole trustee.
Humana Inc. director Kurt J. Hilzinger reported routine equity compensation activity. On 12/31/2025, he acquired restricted stock units tied to his director compensation and dividend reinvestment, including 611 units from reinvested dividends and 357 units from electing to convert cash fees into stock units at a price of $258.8675 per unit. On 01/02/2026, he received an additional 766 restricted stock units as part of his annual director fee, all payable in Humana common stock on a 1-for-1 basis after his board service ends.
Following these transactions, Hilzinger directly beneficially owns 19,448 Humana common shares and holds multiple blocks of deferred restricted stock units, including 24,800 units in one plan-based award. These awards are reported as exempt under Rule 16b-3 and reflect compensation elections rather than open-market buying or selling.
Humana Inc. director Karen W. Katz reported changes in her equity holdings. The filing shows a disposition of 590 shares of Humana common stock. She also reported derivative holdings in the form of restricted stock units (RSUs).
On 01/02/2026, Katz acquired 766 RSUs, which are part of her annual director’s fee payable in stock units and deferred until her resignation, when they will convert into Humana common stock on a one-for-one basis. On 12/31/2025, she acquired an additional 49 RSUs, related to dividend reinvestment on vested and deferred stock units at a price of $258.8675 per underlying share. Some director cash fees were also elected to be converted into deferred stock units, all payable in Humana common stock on a one-for-one basis upon her resignation.
Humana Inc. director Gordon Smith reported changes in his equity holdings. A Form 4 filing shows he disposed of 765 shares of Humana common stock and received additional equity-based awards tied to his director compensation.
The filing reports 766 restricted stock units from his annual director fee, which are deferred and will convert into Humana common stock on a 1-for-1 basis when he leaves the board. It also shows 122 stock units from electing to convert his cash director fees into stock units and 10 additional stock units from the reinvestment of dividends on previously vested and deferred units. All of these awards are structured as deferred stock units payable in Humana common stock, consistent with the company’s director compensation and deferral plan.
Humana Inc. director Raquel C. Bono reported equity awards and deferrals. The filing shows she acquired 766 restricted stock units as part of her annual director fee, which she elected to receive in stock units rather than cash. These units are deferred until she resigns from the board, at which time they will be settled in Humana common shares on a one-for-one basis under the company’s 2019 Amended & Restated Plan.
She also reported 34 additional stock units from dividend payments that were reinvested on already vested and deferred stock units. These dividend units are likewise deferred until she leaves board service and will then be paid in Humana common stock on a one-for-one basis.
Humana Inc. reported an insider equity transaction by its Chief Human Resources Officer, Michelle A. O'Hara. On 01/01/2026, she acquired 2,353 shares of Humana common stock through a transaction coded "M," at an exercise price of $0, reflecting the vesting or exercise of previously granted equity awards.
On the same date, she disposed of 1,093 shares, coded "F," at a price of $258.8675 per share, to cover tax liabilities related to shares vesting on that date, with no value received in return. After these transactions, she beneficially owned 9,541 shares of Humana common stock, which includes 7,512 restricted stock units that each represent a contingent right to receive one share under the company's 2019 Amended & Restated Plan.
Humana Inc. reported insider share transactions by its Chief Financial Officer, Celeste Mellet, dated 12/15/2025. She acquired 2,128 shares of Humana common stock at a price of $0, and 1,222 shares were disposed of at $270.155 per share to pay tax liabilities on vesting shares, with no value received in return.
Following these transactions, Mellet beneficially owned 28,454 Humana shares directly. This total includes 27,548 restricted stock units, each representing a contingent right to receive one share of Humana common stock under the Company's 2019 Amended & Restated Plan.
Humana Inc. Chief Information Officer Japan Mehta reported equity compensation activity in Humana common stock. On 12/15/2025, 1,194 shares were acquired at a reported price of $0, and 470 shares were disposed of at $270.155 to satisfy tax liability related to shares vesting on that date, with no value received in return.
After these transactions, Mehta beneficially owned 8,158 Humana shares directly. This total includes 7,434 restricted stock units that represent a contingent right to receive one share of Humana common stock each under the company’s 2019 Amended & Restated Plan. The report was signed on 12/17/2025.
Humana Inc. disclosed an insider stock transaction by its President, Enterprise Growth, David Dintenfass. On 12/15/2025 he exercised stock options for 2,032 shares of Humana common stock at an exercise price of $0 under the company’s 2019 Amended & Restated Stock Incentive Plan.
On the same date, 918 shares were disposed of at $270.155 per share to cover tax liabilities on vested restricted stock units, leaving 15,316 shares of common stock held directly, including 11,202 restricted stock units that each represent a right to receive one share. He also continues to hold stock options covering 51,389 shares at an exercise price of $367.21 per share, expiring on 02/21/2031 and vesting in three annual installments from 02/21/2025 through 02/21/2027.
Humana Inc. executive Sanjay K. Shetty, President of CenterWell, reported multiple equity award transactions dated 12/15/2025. He acquired 1,968 and 308 Humana common shares through equity awards at $0 per share, and disposed of 888 and 139 shares at $270.155 per share to satisfy tax liabilities on vesting, with no additional value received.
After these transactions, he directly beneficially owns 10,847 Humana common shares, which includes 8,818 restricted stock units that each represent a contingent right to one share. He also holds stock options covering 3,964 shares at an exercise price of $487.1602 expiring 04/01/2030 and 6,572 shares at $367.21 expiring 02/21/2031, all granted under Humana’s 2019 Amended & Restated Stock Incentive Plan.
Humana Inc. executive Michelle A. O'Hara reported routine equity compensation activity. On 12/15/2025, she acquired 1,401 shares of Humana common stock at $0 per share through a transaction coded "M". On the same date, 632 shares coded "F" were disposed of at $270.155 per share to cover tax liabilities on shares vesting that day, with no value received in return. After these transactions, she beneficially owned 10,634 shares, including 9,865 restricted stock units that each represent a contingent right to receive one share of Humana common stock under the company's 2019 Amended & Restated Plan.
Humana Inc.'s president and CEO James A. Rechtin reported equity transactions in company stock dated 12/15/2025.
He acquired 7,707 shares of Humana common stock at $0 per share through an option exercise, then disposed of 3,372 shares at $270.155 per share to satisfy tax liabilities for shares vesting on that date. After these transactions, he indirectly beneficially owned 27,102 shares, including 14,054 restricted stock units, held in revocable trusts for himself and his spouse.
He also holds stock options exercisable for 29,230 shares at $458.185 per share until 01/08/2031 and options for 15,772 shares at $367.21 per share until 02/21/2031, plus 4,366 additional restricted stock units.
Humana Inc. Chief Legal Officer Joseph C. Ventura reported several insider transactions in Humana common stock dated 12/15/2025. He acquired 2,046 shares and an additional 360 shares at an exercise price of $0 per share through stock option and restricted stock unit activity. To cover tax obligations on vesting shares, he disposed of 933 and 164 shares at $270.155 per share, with no value received in return.
After these transactions, Ventura beneficially owns 16,530 Humana common shares directly, including 6,250 restricted stock units, and 290 shares held indirectly in the Humana Retirement Savings Plan. He also holds stock options granted under Humana’s 2019 Amended & Restated Stock Incentive Plan covering 4,656, 4,598, 3,932, 4,162 and 6,572 shares, with exercise prices from $350.7875 to $510.2425 and expirations between 02/24/2027 and 02/21/2031.
Humana Inc. officer and President, Insurance, reported insider equity transactions dated 12/15/2025. He acquired 2,106 and 360 shares of Humana common stock at $0 per share through the vesting or exercise of equity awards, then disposed of 830 and 142 shares at $270.155 per share to pay tax liabilities on restricted stock vesting. After these transactions, he beneficially owned 15,459 shares directly and 525 shares indirectly through the Humana Retirement Savings Plan. His holdings also include 4,162 and 6,966 stock options, 9,059 restricted stock units representing contingent rights to receive common shares, and 172 phantom stock units linked to Humana common stock.
Humana Inc. executive John-Paul W. Felter, SVP, Chief Accounting Officer & Controller, reported equity award activity dated 12/15/2025. Two transactions coded "M" show 455 and 115 shares of Humana common stock acquired at $0 per share as restricted stock units converted into stock under the company’s 2019 Amended & Restated Stock Incentive Plan.
To satisfy tax liabilities on the vesting that occurred on 12/15/2025, transactions coded "F" show 209 and 53 shares disposed of at $270.155 per share, with no value received in return. After these transactions, he directly beneficially owned 1,734 Humana common shares, including 748 restricted stock units that each represent a contingent right to receive one additional share.
Humana Inc. (HUM) director Gordon Smith reported insider activity on 11/01/2025. He acquired 765 shares of Humana common stock via transaction code M at a reported price of $0, bringing his directly held common shares to 765.
The filing also lists deferred equity: 783 restricted stock units tied to the annual director fee and 378 stock units from electing to convert cash fees, each generally payable in Humana common stock on a 1‑for‑1 basis per the director’s elections.
George Renaudin II, an officer of Humana Inc. (HUM), reported changes in his beneficial ownership on transactions dated 10/01/2025. The filing shows 609 restricted stock units vested/added (transaction code M) and a disposition of 240 shares sold at $253.12, leaving him with 16,071 shares directly beneficially owned after the sale.
The Form 4 also discloses outstanding equity awards: stock options covering 4,162 shares with a conversion/exercise price of $510.2425 (exercisable 02/24/2030) and 6,966 shares with a $367.21 exercise price (exercisable 02/21/2031). The filing notes 11,165 restricted stock units included in the total and 172 phantom stock units held indirectly under the company plans.
David T. Feinberg, a director of Humana Inc. (HUM), reported changes in his beneficial ownership on a Form 4 covering transactions dated 09/30/2025. The filing shows a disposition of 441 shares of Humana common stock. It also reports holdings and movements in restricted stock units: 1,593 restricted stock units described as annual director fees deferred, an acquisition of 69 restricted stock units at a reported price of $257.7925, and 17 additional shares/units. The director elected to defer cash fees and dividend payments into stock units, which will be paid 1-for-1 in common stock upon his resignation.
Kurt J. Hilzinger, a director of Humana Inc. (HUM), reported changes in beneficial ownership on Form 4. The filing shows previously held Humana common shares and restricted stock units (RSUs) that are deferred and payable 1-for-1 in common stock upon his resignation as a director. The report records 24,034 RSUs and 2,753 deferred dividend stock units previously held, and a transaction on 09/30/2025 acquiring 364 RSUs at a price of $257.7925, resulting in 15,408 shares reported as beneficially owned following the transaction. Explanations state these RSUs arise from annual director fees, dividend reinvestment, and an elected conversion of cash fees into stock units, all deferred under the company plan and claimed exempt under Rule 16(b)-3.
Gordon Smith, a director of Humana Inc. (HUM), reported changes in his holdings of Humana restricted stock units and common stock rights. The Form 4 discloses transactions dated 09/30/2025: 124 restricted stock units were acquired at a reported unit value of $257.7925, representing a right to receive one share per unit. The filing also shows a disposition of 765 restricted stock units and reports 783 restricted stock units held that represent deferred annual director fees and contingent rights to receive one share per unit under the company’s 2019 Amended & Restated Stock Incentive Plan.
The filing explains that some stock units arise from annual director fees deferred by election and from conversion of cash fees into stock units; all such units are payable one-for-one in Humana common stock when paid and some are exempt under Rule 16b-3.